Clinical Research

14th Feb

VICTORION-1 PREVENT

A research study to find out if Inclisiran can help prevent cardiovascular events (such as heart attacks, strokes, procedures to improve blood flow, and death) in adults who are at high cardiovascular risk but have not had a major cardiovascular event, and who also have high cholesterol. This is often referred to as “primary prevention”.

Having a lot of LDL-cholesterol (also known as “bad” cholesterol) in your blood can lead to build up on your artery walls (a condition called atherosclerotic cardiovascular disease), creating a thick and fatty deposit (or plaque) that can block blood flow. Blocked arteries can lead to important cardiovascular events, such as heart attack, stroke, or cardiovascular-related death.

Inclisiran has been shown to be safe and effective at lowering LDL-cholesterol. This study will help understand if a reduction in LDL-cholesterol with inclisiran will also prevent these important cardiovascular events from occurring.

Approximately 14,000 participants in approximately 45 countries will participate in this study.

Eligible patients will be contacted by the surgery - use the reply link in the text, or alternatively email

ciosicb.research.penryn@nhs.net with VICTORION in the subject line.

THE TRIAL LEAFLET IS AVAILABLE HERE

10th Feb 2023

HARMONIE

Help us protect babies from respiratory infections in the future.

All babies may benefit from protection from RSV - a virus that can cause respiratory infection such as bronchiolitis and pneumonia.

RSV is a common seasonal virus that infects nearly all babies by their second birthday. Most of the time it causes a mild illness, like a cold. However, for some babies it leads to more severe lung problems such as bronchiolitis and pneumonia.

RSV infection is unpredictable and is a leading cause of hospitalisations in babies. Most hospitalisations due to RSV occur in otherwise healthy babies, and it is difficult to know which babies will develop severe disease requiring medical care.

The HARMONIE Research Study follows on from other research studies which have been completed and is looking at how strongly babies can be protected from serious illness due to RSV infection by giving them a single antibody dose. More than 3000 babies have already been given this antibody dose and were monitored closely in clinical trials. These trials have shown that this antibody dose has been well tolerated and has shown good safety results.

More information, including the specifics of what is involved, can be found here: https://rsvharmoniestudy.com/en-gb

If you have been sent a text from Penryn Surgery inviting your child to participate, and are interested, please use the reply link in the text message and we'll be in touch to discuss more. Alternatively email

ciosicb.research.penryn@nhs.net with HARMONIE in the subject line.

Children must be aged 0-12 months, born after 31st March 2022, and born at more than 29 weeks gestation (i.e. no more than 11 weeks premature).

PLEASE NOTE THIS TRIAL HAS NOW CLOSED TO NEW PARTICIPANTS

23rd Mar 2021

MET52

The MET52 Trial is a Childhood immunisation trial looking at providing additional protection to babies against Menigitis A, C, Y and W.

When babies attend their 6-8 week newborn check your GP will discuss immunisations and can provide further information on this trial if you are interested to enrol your child.

Inclusion criteria are babies born over 37 weeks gestation, weighing more than 5lb 8oz at birth. They cannot have already begun to receive their vaccinations and they must be aged between 56-89 days on the day of their first trial visit.

PLEASE NOTE THIS TRIAL HAS NOW CLOSED TO NEW PARTICIPANTS

8th Jan 2021

PROVENT TRIAL

We are currently recruiting participants for a new Covid immunsation study called PROVENT, beginning 13th January 2021.

For patients over 18 years of age and under 60 years of age, if you are in a public-facing role, but not a carer, who believes that your job or living situation puts you at increased risk of exposure to Covid-19, and are interested in participating in the trial of a new vaccine please email this address:

nhskernowccg.research.penryn@nhs.net

Please give your full name, date of birth, occupation and contact number

We cannot guarantee that everyone who would like to participate will be invited onto the trial.

PLEASE NOTE THIS TRIAL HAS NOW CLOSED TO NEW PARTICIPANTS